Logo

PBH

Prestige Consumer Healthcare Inc.

PBH

Prestige Consumer Healthcare Inc. • NYSE
$59.55 ▼ -0.05% (-0.03)
Market Cap $2.94 B
52w High $90.04
52w Low $57.25
Dividend Yield 0%
P/E 14.74
Volume 301.52K
Outstanding Shares 49.44M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2026 $274.114M ▲ $74.401M ▲ $42.211M ▼ 15.399% ▼ $0.86 ▼ $86.832M ▲
Q1-2026 $249.53M ▼ $63.393M ▼ $47.466M ▼ 19.022% ▲ $0.96 ▼ $79.646M ▼
Q4-2025 $296.755M ▲ $87.283M ▲ $50.128M ▼ 16.892% ▼ $1.01 ▼ $91.97M ▼
Q3-2025 $290.317M ▲ $69.087M ▼ $61.032M ▲ 21.023% ▲ $1.23 ▲ $98.477M ▲
Q2-2025 $283.548M $73.043M $54.377M 19.177% $1.1 $89.511M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2026 $119.106M ▼ $3.442B ▲ $1.617B ▲ $1.825B ▼
Q1-2026 $139.502M ▲ $3.432B ▲ $1.576B ▲ $1.855B ▲
Q4-2025 $97.884M ▲ $3.402B ▲ $1.567B ▲ $1.835B ▲
Q3-2025 $50.874M ▼ $3.329B ▲ $1.541B ▼ $1.788B ▲
Q2-2025 $51.54M $3.317B $1.585B $1.732B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2026 $42.211M ▼ $57.486M ▼ $-2.929M ▼ $-74.949M ▼ $-20.396M ▼ $55.384M ▼
Q1-2026 $47.466M ▼ $79.013M ▲ $-1.938M ▲ $-36.282M ▼ $41.618M ▼ $78.175M ▲
Q4-2025 $50.128M ▼ $61.848M ▼ $-3.479M ▲ $-11.488M ▲ $47.01M ▲ $58.369M ▼
Q3-2025 $61.032M ▲ $65.091M ▼ $-9.816M ▼ $-53.865M ▼ $-666K ▼ $63.525M ▼
Q2-2025 $54.377M $69.8M $-2.027M $-51.2M $17.284M $67.773M

Revenue by Products

Product Q3-2025Q4-2025Q1-2026Q2-2026
Analgesics
Analgesics
 $30.00M ▲$30.00M ▲$30.00M ▲$30.00M ▲
Cough and Cold
Cough and Cold
 $30.00M ▲$30.00M ▲$20.00M ▼$30.00M ▲
Dermatologicals
Dermatologicals
 $30.00M ▲$30.00M ▲$30.00M ▲$40.00M ▲
Eye and Ear Care
Eye and Ear Care
 $50.00M ▲$50.00M ▲$30.00M ▼$30.00M ▲
Gastrointestinal
Gastrointestinal
 $70.00M ▲$70.00M ▲$60.00M ▼$60.00M ▲
Oral Care
Oral Care
 $20.00M ▲$30.00M ▲$20.00M ▼$20.00M ▲
Other OTC
Other OTC
 $0 ▲$0 ▲$0 ▲$0 ▲
Womens Health
Womens Health
 $60.00M ▲$60.00M ▲$60.00M ▲$60.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Prestige’s income statement shows a business built around steady, predictable performance rather than rapid growth. Sales have inched higher over the past several years, and profit margins at the gross and operating level are consistently healthy, suggesting good pricing power and tight cost control. The one clear outlier is a year with a reported loss despite solid operating results, which likely reflects a one‑time accounting or non‑cash charge rather than a collapse in the underlying business. Outside of that unusual year, earnings per share have moved up over time, pointing to a stable, mature company that is gradually becoming more profitable on a per‑share basis.

Balance Sheet

Balance Sheet The balance sheet reflects a leveraged but steadily de‑risking profile. Total assets have been fairly stable, while shareholder equity has grown, which is a positive sign for balance sheet strength. Debt has been coming down in recent years, indicating deliberate efforts to deleverage using the company’s strong cash generation. Cash on hand is relatively modest, but that is not uncommon for a predictable, cash‑rich consumer health business. Overall, the financial structure looks more resilient today than a few years ago, though the company still relies meaningfully on debt and needs to keep refinancing and interest-rate risk in mind.

Cash Flow

Cash Flow Cash flow is a key strength. The company reliably converts its earnings into cash, with operating cash flow and free cash flow both steady and comfortably positive over many years. Capital spending needs are low, which means most of the cash generated can be directed toward debt reduction, brand acquisitions, or shareholder returns rather than heavy reinvestment in physical assets. This pattern suggests “high‑quality” earnings and gives management flexibility, though it also means future growth still depends heavily on smart brand management and acquisitions rather than big internal build‑outs.

Competitive Edge

Competitive Edge Prestige competes in over‑the‑counter health categories where brand trust matters a lot. Its portfolio includes many well‑known, long‑standing brands that often hold leading positions in narrow niches, such as certain eye care, women’s health, and oral care segments. This brand strength gives the company some pricing power and helps defend against private‑label offerings. The strategy of acquiring overlooked brands from larger players and then revitalizing them has worked well historically. However, the company still operates in a competitive space dominated by much larger consumer health and consumer goods firms, and it remains dependent on retailer shelf space and the willingness of consumers to pay a premium over store brands.

Innovation and R&D

Innovation and R&D Innovation at Prestige is practical and commercial rather than science‑heavy. The company focuses on refreshing existing brands through new formats, updated formulations, cleaner ingredients, and more modern packaging, along with better digital presence and e‑commerce execution. Recent moves toward more control over manufacturing and the supply chain aim to improve reliability and margins, while acquisitions open doors into areas like men’s health and international expansion. The main opportunity is to keep extracting more value from familiar brands and to extend them into adjacent needs. The main risk is that this incremental style of innovation may not be enough if consumer preferences shift quickly or if competitors outspend Prestige on marketing and product upgrades.

Summary

Prestige Consumer Healthcare looks like a mature, brand‑driven healthcare company with steady revenue, strong margins, and very dependable cash flow. It has used that cash to gradually reduce debt and strengthen its balance sheet, while continuing to acquire and polish niche over‑the‑counter brands. The business model relies on brand equity, category leadership in smaller segments, and disciplined execution rather than breakthrough science. Future performance will hinge on its ability to keep brands relevant, integrate recent manufacturing acquisitions, expand in targeted growth areas like men’s health and international markets, and manage competitive and retailer pressures, all while maintaining the cash generation that underpins its current financial strength.

NEWS

November 6, 2025 · 6:00 AM UTC

Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2026 Results

Read more

October 6, 2025 · 5:00 PM UTC

Prestige Consumer Healthcare to Release Fiscal 2026 Second Quarter Earnings Results

Read more

September 4, 2025 · 7:00 AM UTC

Prestige Consumer Healthcare to Present at the Barclays Global Consumer Staples Conference

Read more